Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients
Introduction
Allergic rhinitis (AR) represents a global health care problem that greatly affects daily activity, work productivity, learning, sleep, and quality of life (QOL) in people of all ages [1]. Japanese cedar pollinosis (JCP) is a unique allergic disease not seen outside of Japan. A massive amount of pollen is dispersed in the spring. The disease affects many people in cities far from the source of the pollen because pollen travels long distances. The disease has high morbidity (35%) in the adult Japanese population and the prevalence of JCP is increasing [1], [2].
Allergen-specific immunotherapy (IT) is recognized as the only curable treatment for AR. Subcutaneous immunotherapy (SCIT) has been used for treating AR in Japan. However, SCIT has several drawbacks such as the requirement for frequent hospital visits, injection site pain, and the risk of rare serious adverse drug reactions such as anaphylaxis [3]. Sublingual immunotherapy (SLIT) was developed to overcome these drawbacks and can be administered at home under a physician's direction. However, SLIT should be started after a correct diagnosis of AR and administered by the appropriate method [4], [5].
Clinical trials have demonstrated the effectiveness of SLIT for patients with JCP [6], [7]. National health insurance in Japan has covered SLIT for JCP since October 2014 and for house dust mite (HDM) since 2015. Based on research by the Japanese Rhinologic Society (JRS), the present guideline was prepared to provide accurate knowledge of SLIT and to contribute to the development of this therapy [8]. The JRS is an independent academic organization that receives no sponsorship or funding from specific organizations or businesses. Furthermore, the JRS has not obtained funds for the preparation of the present guidelines from any businesses, which include businesses representing the pharmaceutical industry.
Section snippets
Criteria for determining recommendation grades
This article discusses some clinical questions (CQs). Clinical questions were prepared with regard to the procedures, effects, adverse reactions, and mechanisms of SLIT. The literature published between January 2003 and December 2012 was searched for evidence using the databases of PubMed, the Cochrane Library, and the Japan Medical Abstracts Society (Web version 4). The principal search period was between October 2012 and June 2013 and the main search terms were “allergic rhinitis”,
CQ1: does SLIT improve symptoms and QOL in patients with seasonal allergic rhinitis?
A meta-analysis of randomized placebo-controlled double-blind trials (RCTs) on the use of SLIT for seasonal allergic rhinitis (SAR) demonstrated that symptom scores and medication scores improved significantly in the active treatment group (Level Ia) [9], the symptoms of the active treatment group improved in all trials, and a significant effect was observed in 21 (58%) of 36 trials (Level Ia) [10], and that high efficacy rates were observed in adults and in patients who received preseason
Conflicts of interest
Organizations or businesses that have provided research funding (for contract research, joint research, clinical trials, etc.), scholarship donations, and monetary compensations for lectures, manuscripts, and pamphlets to members of the guideline preparation committee are the following (the period of interest is between January 2012 and December 2013): Astellas Pharma, Inc. (Tokyo, Japan), AstraZeneca K.K. (Osaka, Japan), Bayer Yakuhin, Ltd. (Osaka, Japan), Chugai Pharmaceutical Co., Ltd.
References (86)
- et al.
Guiding principles of subcutaneous immunotherapy for allergic rhinitis in Japan
Aurus Nasus Larynx
(2014) - et al.
Examination, diagnosis and classification for Japanese allergic rhinitis: Japanese guideline
Auris Nasus Larynx
(2012) - et al.
Japanese guideline for allergic rhinitis 2014
Allergol Int
(2014) - et al.
A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis
Allergol Int
(2008) - et al.
Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systemic review and meta-analysis
J Allergy Clin Immunol
(2010) - et al.
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials
Ann Allergy Asthma Immunol
(2006) - et al.
Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis
J Allergy Clin Immunol
(2004) - et al.
Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis
J Allergy Clin Immunol
(2004) - et al.
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study
Ann Allergy Asthma Immunol
(2008) - et al.
Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study
J Allergy Clin Immunol
(2010)